of benefit and 24.5% (170/693) required an 80% or greater risk reduction with a mean absolute risk reduction of 11.9% (CI:11.4-12.5) before indicating they would initiate treatment. Conclusions: Individualized estimates of 10-year absolute fracture risk affect fracture prevention attitudes. Many women require fracture risk reductions that exceed the benefits of most currently available treatments. Aims: Most peripheral fractures are preceded by a fall and many of the same risk factors account for falling and fractures. Given the relatively low frequency of fractures, number of falls is often used as a surrogate endpoint for fracture. However, there exist few reports that directly compare differences in the epidemiology of falls in diverse populations with different incidence of hip fractures. The aim of this study was to evaluate fall epidemiology in elderly men. Methods: Included were elderly men in Hong Kong (n=2000, ages 65-92 years), United States (n=5995, ages 64-100 years) and Osteoporos Int (2010) Aims: Current osteoporosis treatment guidelines use absolute 10-year fracture risks, but it is not known if these risks are meaningful to patients. We assessed the impact of absolute risk information on fracture prevention attitudes using a web-based decision tool. We also estimated the minimum acceptable absolute risk reduction women demand of osteoporosis treatment. Methods: Our study included a clinical group with t-score<-1.0 and an internet group with high fracture risk visiting the "YourDiseaseRisk" website. We report data for untreated women with estimated 10-year absolute fracture risks >10%. Each rated fracture prevention importance on a Likert scale (unimportant to very important) before and after seeing her 10-year absolute fracture risk depicted graphically alongside the 10-year risk for a typical woman her age. To identify the minimum fracture risk reduction that women required to initiate osteoporosis treatment, absolute fracture risk was shown both with and without treatment in sideby-side 100-face pictograms. Relative treatment benefit was systematically improved in successive scenarios. Proportions, means, and 95% confidence intervals (CI) were estimated to characterize the impact of absolute risk information on perceived importance of fracture prevention and minimum demanded risk reduction. Results: Among 967 participants (101 clinical, 866 internet; mean age 63), 71% gave fracture prevention the highest importance rating at study entry (n= 690). For these women, provision of personalized risks lowered importance ratings among 10.1% (CI: 7.9-12.4) with none rating prevention as unimportant. For the remaining women (n=277), importance ratings increased among 17.3% (CI: 12.9-21.8) with most giving prevention the highest rating; ratings decreased among 7.6% (CI: 4.4-10.7) with prevention rated as unimportant among fewer than 5%. 693 women completed the demanded risk reduction exercise. The mean demanded absolute risk reduction was 6.9% (CI: 6.6-7.3). A minority (16.3%, n=111/693) would not take medication at any level 
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Sweden (n=3014, ages 69-81 years), who comprised the MrOS International Study (n=11009). At baseline epidemiology of falls during the preceding year was evaluated by a questionnaire. Results: During one year, 1207 men (11.0%) fell one time and 863 (7.8%) two or several times. In this report we evaluate the men in 5-year classes. Fall frequency increased significantly with advancing age so that the annual incidence of falls ranged from 16.5% in ages 64-69 years, to 43.2% in ages >90 years (groups comparisons p<0.001). There was no difference in the proportion of frequent fallers in the different 5 year classes, the annual incidence varying between 38.3%>51.2%, p=0.14).
The proportion of fallers was in most ages highest in US, intermediate in Sweden and lowest in Hong Kong (in age group 70-74 years the proportions were 18.6%, 15.4% and 14.4%, respectively; p=0.01). The proportion of frequent fallers showed a different pattern, being highest in Sweden, intermediate in US and lowest in Hong Kong (in age group 70-74 years the proportions were 50.8%, 44.3% and 20.6%, respectively; p<0.001). The fall epidemiology did not differ when comparing Asian men living in Hong Kong or US whereas white men living in Sweden had a higher frequency of one or more falls than white men living in US, in age group 75-79 years with the proportions 22.2% and 17.2%, p<0.001). Conclusions: These findings indicate that among older men, the risk for any fall increases with advancing age; however the risk of frequent falls is not significantly different across age groups. Risk of falls is different in different geographic regions. When using falls as surrogate endpoint for fractures, we must take into account both number of fallers and the proportion of frequent fallers. In addition, this survey indirect indicates that both ethnicity and environmental factors may influence the fall risk.
Thus Pearson correlations for 11-19 week and 19-34 week growth respectively with bone indices at 4 years: BA (r=0.19, p=0.001; p=0.93) , BMC (r=0.24, p<0.001; r=0.07, p=0.21), aBMD (r=0.24, p<0.001; r=0.13, p=0.03) . Conclusions: Bone mineral at birth is predicted by rate of abdominal circumference growth in late pregnancy more strongly than by growth in early pregnancy. By 4 years old the pattern is reversed. This suggests that the child reverts to the early growth trajectory during the first few years of postnatal life. Further work is needed to elucidate the extent to which perturbations of growth in later pregnancy may alter this natural pattern. Aims: Traumatic fractures affect nearly one out of two healthy children, with a maximal incidence concomitant to peak height velocity (PHV). It has been hypothesized that bone fragility at that time results from a transient deficit in bone mineral accrual relative to bone size. The influence of fracture history on bone mineral density, cortical and trabecular microstructure was studied in a cohort of 176 healthy young boys aged 15.2±0.5 (±SD) yrs and prospectively followed from age 7.5±0.5 yrs. Results: 156 fractures were recorded in 87/176 boys with peak incidence between 10 and 14 yrs. Most common fractures were localized in forearm and wrist (40%), followed by hand/fingers (18%) and arm/shoulder (14%). 20% affected the lower limb (including foot, ankle, tibia, femur) and 8% others sites. 38 boys reported multiple fractures (2 to 5), accounting for 2/3 of all fractures; in this case the upper limb was always affected. Whereas no significant difference was observed at the distal radius for aBMD as well as for the volumetric and microstructure parameters, subjects with a positive fracture history (n=87) had lower femoral neck (0.847±0.116 vs. 0.901±0.133 g/cm 2 , P=0.005) and total hip aBMD (936±133 vs. 992±139 g/cm 2 , P=0.007) as compared to boys without fractures (n=89), corresponding to a delta Z-score of -0.45 at the femoral neck. Boys with a fracture history displayed at the distal tibia lower trabecular vBMD (196±27 vs. 205±27 mg HA /cm 3 , corresponding to a delta Z-score of -0.34, P=0.029) and number (2.04±0.26 vs. 2.13±0.31 mm -1 , P=0.040) and greater trabecular spacing (418±60 vs. 398±62 mm, P=0.028). The statistical significance of these differences remained similar after adjustment for standing height, body weight, calcium and protein intakes, physical activity, pubertal stage, calcium supplement or placebo randomization between age 7.5 and 8.5 yrs, as well as after exclusion of 7 boys with major lower limb fractures. Conclusions: In healthy adolescent boys fracture history was associated with lower aBMD and trabecular vBMD at weight-bear-Aims: Increased remodeling with its negative bone balance contributes to structural deterioration of the skeleton after menopause. While accelerated trabecular bone loss contributes to bone fragility, cortical bone is a neglected determinant of bone strength even though it comprises 80% of the skeleton. Risedronate (RIS) is effective in reducing the risk for non-vertebral and hip fracture and reduces intra-cortical porosity assessed in iliac crest biopsies 1 . To better understand the structural basis of the anti-fracture efficacy of risedronate, we conducted a 12 month double-blind pilot study among 159 women aged 45-55 years within 36 months since menopause and with osteopenia as determined densitometrically. Methods: Participants were assigned to oral RIS 35mg/week or placebo (PLB) in a 2:1 randomization. Using high resolution pQCT (XtremeCT, Scanco, ~100 µm resolution), microstructural parameters were measured at baseline and 12 months at distal tibia (DT) and distal radius (DR). Results: In the PLB group, total and cortical but not trabecular vBMD decreased in DT relative to baseline. Cortical thickness also decreased from baseline in the PLB group. No treatment differences were detected in trabecular vBMD, BV/TV or other trabecular bone indices in DT or DR. RIS prevented the decline in cortical vBMD in DT (p=0.03, Table) . Similar but less significant (p>0.05) observations were made for cortical thickness at DT and for cortical vBMD and thickness at DR. RIS decreased P1NP (-44.1%) and sCTX (-39.4%) and increased aBMD in the lumbar spine (1.4%) and proximal femur (0.5%) from baseline. Conclusions: Consistent with the reduction of remodeling, these data support the hypothesis that treatment with risedronate reduces the deterioration of cortical microstructure, likely due to the reduction of intra-cortical porosity and may therefore, protect against developing bone fragility in postmenopausal women. Aims: Receptor Activator of NF-κB (RANK) expressed on osteoclasts and their precursors is a receptor for RANK Ligand (RAN-KL). Signals transduced by RANKL-RANK interaction induce genes essential for the differentiation and function of osteoclasts partly through the direct binding of NFATc1 to target gene promoters. We have cloned a 6-kb fragment containing the 5'-flanking region of the mouse RANK gene and found the three putative NFAT binding sites (-370, -550 and -720) . Here, we examined the regulatory mechanism of the RANK gene by RANKL signaling through NFATc1 binding. Aims: Inflammatory bowel diseases (IBD) appearing during childhood and adolescence compromise peak bone mass acquisition and increase fracture risk. The structural determinants of bone fragility in IBD however remain unknown. Methods: We investigated volumetric bone mineral density (vBMD), trabecular and cortical bone microstructure at distal radius and tibia by high-resolution pQCT (XtremeCT, Scanco, Switzerland), aBMD at distal radius, hip and spine and vertebral fracture assessment (VFA) by DXA in 107 young patients (mean age 22.8 yrs, range 12.2-33.7 yrs; 62 females and 45 males) with Crohn's disease (n=75), ulcerative colitis (n=25), undetermined colitis (n=2), and no definitive diagnosis (n=5), and in 389 healthy young individuals. Results: Mean disease duration was 6.1 yrs, 89/107 IBD patients received corticosteroids, 83 other immunomodulators, and 59 vitamin D. Clinical fractures were reported by 38 patients (mean age at 1 st fracture, 12.6 yrs), the vast majority of the forearm, arm or hand; 5 had vertebral crush fractures (Grade 1 or 2) and 11 had multiple fractures. As compared to healthy controls (matched 2:1 for age, sex, height and fracture history), the 102 patients with established IBD had similar weight but significantly lower aBMD at all sites, lower trabecular (Tb) BV/TV and number, and greater Tb separation and inhomogeneous Tb distribution (1/SD TbN) at both distal radius and tibia, lower tibia cortical thickness (CTh), but no differences in cortical vBMD nor bone perimeter. Among IBD's, aBMD was not associated with fractures (by logistic regression adjusted for age, age square, sex, height, weight and protein intake). However, radius and tibia Tb BV/TV, thickness and SD 1/TbN, as well as radius Tb separation and perimeter, were significantly associated with fracture risk (fully adjusted as above), whereas cortical vBMD and CTh were not. After adjustment for aBMD at radius, respectively at femur neck, radius SD 1/TbN and tibia BV/TV, TbTh and perimeter remained independently associated with fracture risk. Conclusions: Young subjects with IBD have low bone mass and poor bone microarchitecture compared to healthy controls. Alterations of bone microarchitecture, particularly in the trabecular bone compartment, are specifically associated with increased fracture risk during growth. Acknowledgement: The Crohn's and Colitis Foundation of America (CCFA) for funding this study Methods: We analyzed this relationship in 3252 male and female patients who participated in a long-term follow-up study (LURIC study) designed to evaluate the impact of genetic polymorphisms and plasma biomarkers on cardiovascular health. Two-thirds of the study population were male and two thirds were found to have significant coronary artery disease. Based on their renal function patients were categorized into KDOQI categories 1 (creatinine clearance >90ml/min/1.73m2; N=1044), KDOQI 2 (60-89 ml; N=1849) and KDOQI 3 (30-59.9 ml; N=359). Serum levels of 25OHD were assayed using a radioimmunoassay (DiaSorin). Results: Age of patients in the respective categories was 56±10, 64±9 and 69±8 years, respectively. There was a rather small, yet significant difference in 25OHD levels across the 3 KDOQI categories 17.1±9.0, 17.8±9.3 and 15.4±9.1 ng/ml. We formed quartiles (QU) of 25OHD levels and the absolute values of 25OHD (median and interquartile range) were: 7.1 (5.8-8.7), 12.8 (11.5-14.3), 19.0 (17.2-20.9) and 30.1 (25.1-33.3) ng/ml and performed an ANCOVA adjusting for age, sex, BMI, average daily physical activity, pro-NT BNP levels, diabetes mellitus, and blood pressure. With decreasing 25OHD QU (QU4 to QU1) there was a proportionally higher increase in PTH levels with declining renal function: 25.7% (KDOQI1), 32.0% (KDOQI2) and 60.8% (KDOQI3), respectively (all P<0.001). Further adjustment for 1,25(OH)2D and serum phosphate levels did not influence this relationship noticeably. Conclusions: We conclude that PTH secretion over a large eGFR range (30 to 120 ml/min/1.73 m 2 ) is almost exclusively regulated by 25OHD and not by 1,25(OH)2D levels as is commonly believed. In addition, a decline in renal function independently of 1,25(OH)2D and serum phosphate levels led to a considerably larger increase in PTH secretion for a given level of 25OHD. Aims: The aim of this study was to determine if single nucleotide polymorphisms (SNPs) in RANKL, RANK and OPG influence volumetric bone mineral density (BMD v ) or bone geometry in men. Methods: Pair-wise tag SNPs (r 2 ≥0.8) were selected for OPG, RANKL and RANK and their 10 kb flanking regions. The SNPs were genotyped in men aged 40-79 years recruited for participation in a population-based study of male aging, the European Male Ageing Study (EMAS). Peripheral quantitative computed tomography (pQCT) measurements were made at the distal (4%) and midshaft (50%) radius in men from two EMAS centres (Manchester, UK and Leuven, Belgium). Total and trabecular BMD v (mg/mm 3 ), and bone cross sectional area (mm 2 ) were measured at the distal radius. Cortical BMD v (mg/mm 3 ); total, cortical and medullary area (mm 2 ); and cortical thickness (mm) were measured at the midshaft radius. Linear regression was used to test the association between SNPs and bone phenotypes under an additive genetic model adjusting for centre. Results are reported as mean change in the outcomes for each copy of the minor allele. Results: Seventy-four SNPs (RANKL: 8, RANK: 44 and OPG: 22) and 589 subjects were included in the analysis. We identified 1 C a number of SNPs in RANKL, RANK and OPG associated with BMD v including rs2073617 in OPG associated with total BMD v (β=9.00; 95% CI=1.73, 16.27; p=0.016) and rs4524035 in RANK associated with trabecular BMD v both at the distal radius (β= -8.59; 95% CI=-16.3, -0.87; p=0.030), and rs10505348 in OPG associated with cortical BMD v at the midshaft radius (β=5.50; 95% CI=0.94, 10.06; p=0.019). The SNP rs10505348 was also associated with higher cortical thickness (β=0.06; 95% CI=0.01, 0.11; p=0.026) and smaller medullary area (β= -2.33; 95% CI=-4.45, -0.21; p=0.031) at the midshaft radius. There were four other SNPs in RANKL associated with medullary area at the midshaft radius including rs633137 (β=4.74; 95% CI=1.13, 8.35; p=0.010). We also identified four SNPs in RANK associated with the distal radius cross sectional area including rs8083511 (β=10.39; 95% CI=2.05, 18.73; p=0.015). Conclusions: Our findings suggest that genetic variation in the RANKL/RANK/OPG signalling pathway influences radius geometry and BMD v (cortical, trabecular and total) in men with some SNPs influencing both. Aims: To present an interim analysis of the International Costs and Utilities Related to Osteoporotic fractures Study (ICUROS) of the quality of life impact of vertebral fractures during the first twelve months after sustaining the fracture and any difference in quality of life (QoL) between hospitalized and non-hospitalized patients in Austria, France, Italy and Russia. Methods: Patients were enrolled from 23 study centers in Austria, France, Italy, and Russia. Patients were asked about their QoL before (recollected), directly after the fracture (within two weeks after fracture), at four months and 12 months after the fracture. The QoL was measured by the EQ-5D questionnaire. Results: A data extraction in January 2010 resulted in a dataset of 253 patients with a vertebral fracture, out of which 21.3% had been hospitalized in connection to this event, however varying markedly between countries (in Russia 11.5% and Austria 51.2%). 85% were women with a mean age of 69 at the time of fracture. There was no significant difference in QoL before fracture between the two patient groups. The result presented in Figure 1 indicates that the effect on quality of life was larger for hospitalized patients compared to non-hospitalized. The effect sustained one year after the fracture. The average QoL loss the first year was estimated at 18.6% and 33.9% for non-hospitalized and hospitalized patients, respectively. Conclusions: Patients who were hospitalized following a vertebral fracture had a larger absolute and relative health related quality of life decrement than non-hospitalized patients. 
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OC4 -IN HEALTHY 15-YEAR OLD BOYS PREVIOUS FRACTURES ARE ASSOCIATED WITH PREFERENTIAL TRABECULAR BONE DEFICIT AT WEIGHT-BEARING SKELETAL SITES
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OC12 -COMPARISON OF PREDICTION MODELS FOR TEN-YEAR RISK OF OSTEOPOROTIC FRACTURES WITH FRAX®: THE JAPANESE POPULATION-BASED OSTE-OPOROSIS (JPOS) COHORT STUDY
Aims:
The objective was to evaluate the ability of the Japanese version of FRAX®, a WHO fracture risk assessment tool, to predict the 10-year probability of osteoporotic fractures. Methods: Major (hip, clinical vertebral, forearm, and proximal humeral) and hip osteoporotic fracture event was ascertained in the 10-year follow-up survey. The subjects for the analysis were 831 women aged 40-74 years at the baseline survey. The ratio of the observed events to the events estimated from FRAX® (O/E ratio) was obtained. The area under the curve (AUC) from receiver operating characteristic curve analysis was obtained for FRAX ® and multiple logistic regression models using age, body weight, and femoral neck bone mineral density (FN BMD). Results: There were no significant differences between any probabilities of observed events and probabilities obtained using FRAX® with or without FN BMD regarding major (O/E ratio, 0.87 with P=0.544; O/E ratio, 0.87 with P=0.568), or hip (O/E ratio, 0.47 with P=0.314; O/E ratio, 0.44 with P=0.210) fractures. AUC values from FRAX® with BMD were similar to those of models using age and FN BMD (Table) . Conclusions: The Japanese version of FRAX ® estimated the 10-year probability of osteoporotic fractures in this population, although it was not superior to models that used only age and FN BMD. Aims: Hip fracture risk depends on fall risk and hip bone strength. Finite element (FE) models explicitly account for bone density/property distribution and bone geometry, the determinants of hip bone strength. The study goal was to evaluate FEcomputed hip strength as a predictor of hip fracture in elderly men and women. Methods: 5500 subjects from the AGES-Reykjavik study age 65-90 years had quantitative CT (QCT) scans of the hip (Siemens Somatom 4, 120 kVp, 150 mAs, 3-mm-thick slices). During 5 to 7 years follow-up, 27 men and 52 women sustained hip fractures. For each fracture subject, roughly 2 sex-and age-matched control subjects (57 men, 104 women) were randomly selected. FE models of the left proximal femur of each subject were created and analyzed under single-limb stance loading. These models used nonlinear material properties and computed the fracture load (FL); analogous models for fall loading are not yet available.
Proximal femur areal bone mineral density (BMD) was computed from the CT scans. Logistic regression was used to identify hip fracture predictors separately in men and women, and odds ratios (OR) per standard deviation were computed with adjustment for age, height and weight. Results: FL was significantly associated with hip fracture in both men and women (p<0.002), and OR values increased after controlling for age, height and weight (Table) . Aims: Traditional predictors of radiological progression in rheumatoid arthritis (RA) are mostly markers of inflammation. We investigated to what extent baseline measurements of the ratio of receptor activator of nuclear factor κB ligand (RANKL) / osteoprotegerin (OPG) and C-terminal cross linking of type-I and type-II (CTX I and CTX-II) in addition to traditional markers of disease severity, could predict annual radiological progression. Methods: A cohort of 155 early, active, untreated RA patients that participated in the COBRA trial was followed for 11 years. Urine was sampled at baseline and after 3 months from start of treatment and analyzed for CTX-I and CTX-II. Baseline serum samples were analyzed for RANKL and OPG. Available traditional markers of disease severity included baseline measurements of erythrocyte sedimentation rate, rheumatoid factor and baseline radiological damage. A digital database of frequent radiographs was available, scored according to the Sharp/van der Heijde method. Individual annual progression rates were calculated and used as outcome variable. Multiple linear regression analyses identified the strongest predictors of annual radiological progression. Results: In multivariable analyses the RANKL:OPG ratio and CTX-I or CTX-II proved to be independent predictors of annual radiological damage over 11 years. The prediction of annual radiological progression was strongest when the RANKL:OPG ratio and CTX1 or CTX2 were evaluated in the same model (36-39% explained variance). Adding the effect of treatment at 3 months to the baseline models improved the predictive ability of the models up to 44-46%. Conclusions: Unfavorable baseline levels of the RANKL:OPG-ratio as well as CTX-I (markers of bone resorption) and CTX-II (a marker of predominantly cartilage degradation) in patients with early, active, untreated RA are strong independent predictors of rapid and persistent damage progression over 11 years follow up. Early improvement in bone markers on treatment predicts a better outcome. Aims: Denosumab (DMAb) is a fully human antibody that inhibits RANKL, an essential mediator of osteoclast formation, function, and survival. In the FREEDOM trial, DMAb significantly reduced the risk of fractures.
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OC16 -EVALUATION OF HEALTH-RELATED QUALITY OF LIFE IN POSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS WHO PARTICIPATED IN THE FREEDOM TRIAL
1 In fracture trials with other osteoporosis therapies, no difference between treatment groups in health-related quality of life (HRQoL) was observed.
2,3 Here we evaluate the effect of DMAb on HRQoL, and the association of all incident clinical fractures, regardless of treatment group, with HRQoL, in the women who participated in the FREEDOM trial. Methods: The FREEDOM trial enrolled 7,868 women aged 60-90 years with a total hip and/or lumbar spine DXA T-score <-2.5 and not <-4.0 at either site. Women were randomized to receive DMAb 60 mg sc every 6 months or placebo, in addition to daily calcium and vitamin D. HRQoL was assessed with the Osteoporosis Assessment Questionnaire-Short Version (OPAQ-SV) at baseline and every 6 months for 3 years. The OPAQ-SV has 34 disease-specific questions in 3 HRQoL dimensions of physical function, emotional status, and back pain. Higher scores represent better health status. Results: OPAQ-SV completion rates at year 3 were 83%. There were no significant differences between treatment groups in HRQoL measures when comparing baseline to year 3. However, compared with women without any fractures, women with incident clinical fractures, regardless of treatment group, reported declines in OPAQ-SV physical function and emotional status dimensions at year 3 (P<0.0001; Table) .
Conclusions:
As observed in similar studies with other osteoporosis therapies, statistically significant differences in mean change in HRQoL from baseline to end of study were not found when comparing treatment groups. However, incident clinical fractures were associated with significant decreases in HRQoL at year 3, as assessed by the OPAQ-SV. Future analyses will incorporate the effects of time elapsed since fracture. Aims: In a pivotal 3-year phase 3 study, bazedoxifene (BZA) was shown to significantly reduce new vertebral fracture risk in postmenopausal women with osteoporosis, and in a subgroup of women at higher fracture risk, to decrease the risk of nonvertebral fracture (NVF). Here we describe the efficacy of BZA in preventing fractures over 5 years of therapy.
Methods:
The core study enrolled generally healthy postmenopausal women aged 55 to 85 years (N=7,492; mean age, 66.4 y) with osteoporosis, defined as lumbar spine (LS) or femoral neck (FN) T-scores ≤-2.5 and no prevalent vertebral fracture or LS and FN T-scores ≥-4.0 with prevalent vertebral fracture. Eligible subjects were randomized to daily treatment with BZA 20 or 40 mg, raloxifene (RLX) 60 mg, or placebo; subjects received supplemental elemental calcium (1,000-1,200 mg/d) and vitamin D (400-800 IU/d). A total of 4,216 subjects were enrolled in the extension study (Years 4 and 5). The RLX 60-mg treatment arm was discontinued in the fourth year and subjects receiving BZA 40 mg were transitioned to BZA 20 mg (BZA 40/20 mg) after 4 years. Findings at 5 years are reported for BZA 20 mg, BZA 40/20 mg, and placebo only. The primary endpoint was the incidence of new vertebral fractures; the incidence of NVFs was a secondary endpoint.
Results: At 5 years, Kaplan-Meier estimates of the incidence of new vertebral fractures in the intent-to-treat population was significantly reduced with BZA 20 mg (4.5%) and BZA 40/20 mg (3.9%) compared with placebo (6.8%), corresponding to relative risk reductions of 35% (P=0.014) and 40% (P=0.005), respective-
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ly. There was no difference in NVF rates among subjects treated with BZA 20 mg (9.5%), BZA 40/20 mg (7.6%), or placebo (9.0%) in the overall population. An analysis of a higher-risk subgroup (femoral neck T-score ≤-3.0 and/or ≥1 moderate or ≥2 mild vertebral fractures; n=1324) showed a 37% (P=0.06) and 31% (P=0.16) reduction in NVF rates with BZA 20 mg and BZA 40/20 mg, respectively, relative to placebo. Overall, BZA showed a favorable safety and tolerability profile over 5 years of treatment. Conclusions: Overall findings at 5 years were similar to those observed at 3 years, and support a sustained anti-fracture effect of BZA 20 mg on new vertebral fractures in postmenopausal women with osteoporosis and on NVFs in a subgroup of women at higher risk for fracture. Aims: Inhibition of sclerostin by treatment with a sclerostin antibody (Scl-Ab) has been shown to increase bone formation and restore bone mass and bone strength in ovariectomized (OVX) rats with established osteopenia. In the current study, we examined whether pretreatment with the anti-resorptive agent alendronate (ALN) would result in a blunting of the bone anabolic effects induced by Scl-Ab in OVX rats. Methods: Ten-month-old OVX rats (3.5 months post-OVX) were treated with ALN (0.028 mg/kg, SC, 2x/week) for 6 weeks and then transitioned to Scl-Ab (25 mg/kg, SC, 1x/week) alone, or to a combination of Scl-Ab plus ALN (n=10/group) for an another 6 weeks. As additional controls for the study, a separate set of OVX rats were treated with vehicle for 6 weeks and then transitioned to Scl-Ab alone, or to vehicle for another 6 weeks (n=10/group). Results: Histomorphometric analysis of the 3 rd lumbar vertebral bodies revealed that 6 weeks of ALN treatment significantly reduced trabecular mineralizing surface (MS/BS), mineral apposition rate (MAR) and bone formation rate (BFR/BS) in OVX rats. Transition to Scl-Ab from ALN or vehicle was equally effective at restoring trabecular bone volume (BV/TV) and increasing trabecular thickness (Tb.Th), indicating that ALN pretreatment did not blunt the bone restorative effects of Scl-Ab in OVX rats. Consistent with these findings, dynamic histomorphometric analysis showed that transition to Scl-Ab from ALN or vehicle was equally effective at increasing trabecular MS/BS, MAR, and BFR/BS at lumbar vertebrae. Similar findings for MS/BS, MAR, and BFR/BS were observed on both the periosteal and the endocortical surfaces of the tibial shaft. Transition to Scl-Ab from ALN or vehicle was equally effective at increasing serum osteocalcin, a marker of bone formation. Furthermore, BV/TV, Tb.Th, trabecular and cortical bone formation parameters, and serum osteocalcin did not differ significantly between Scl-Ab alone and the combination of Scl-Ab plus ALN in OVX rats pretreated with ALN. Conclusions: The increases in bone formation and bone mass resulting from treatment with a sclerostin antibody, with or without alendronate co-administration, were not blunted by pretreatment with alendronate in OVX rats. These data suggest that the anabolic effects of sclerostin antibody are independent from activation of bone resorption.
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OC18 -SKELETAL EFFECTS OF A SCLEROSTIN ANTIBODY ALONE OR IN COMBINATION WITH AN ANTI-RESORPTIVE AGENT IN OVARIECTOMIZED RATS PRETREATED WITH AN ANTI-RESORPTIVE AGENT
nal visit between months 10-12. RON (200, 300, and 400 mg) increased LS BMD more than PBO (1.4-1.9%); ALN and TER increased LS BMD 4.7% and 9.2%, respectively. RON (200-400 mg) caused small but statistically significant decreases in total hip (TH) BMD. ALN and TER increased TH BMD by 2.8% and 2.6%, respectively. Median increases in serum CTx were >20% on RON (200-400 mg) at month 6, reaching a maximum of 58% at month 10. In comparison, TER produced a median increase of 57% at month 3 and reached a maximum of 103% at month 10. P1NP had a median increase over baseline up to 38% in the RON groups (200, 300, 400 mg) at week 4 vs. a median increase of 98% for TER. P1NP reached a maximal median increase up to 148% in the RON groups at month 10 as compared to the maximal median increases of 151% for TER at month 6. Serum calcium showed dose-dependent elevations at pre-and post-dose in the RON groups as early as week 1. Pharmacokinetic data revealed that PTH(1-84) AUC was larger in the RON groups compared to historical data with TER. We hypothesized that RON induced a mild sustained hyperparathyroidism. An observational extension study followed subjects off study for 6-12 months. LS BMD changed from the month 10-12 endpoint in the PBO group by -1.5%. Changes in the RON 100, 200, 300, and 400 mg and ALN groups were 1.4%, 0.1%, -0.9%, 1.3%, 0% respectively. At the TH, changes were minimal for the PBO, RON 100, 200, 300, and 400 mg and ALN groups, respectively: -1.2%, +0.2%, -0.1%, -0.6, +0.1%, and -1.7%. Conclusions: These findings are consistent with the hypothesis that ronacaleret, due to a prolonged pharmacodynamic effect, induced a mild primary hyperparathyroidism and did not produce therapeutically promising effects on bone density. 2 ) to identify blinded randomized clinical trials which evaluated fracture efficacy of osteoporosis therapies in postmenopausal women. A meta-analysis was conducted with random effect models using relative risks (RR) based on raw events for the number of patients with a fracture during follow-up. Treatment effect was measured using RR for adjusted indirect comparisons (Bucher et al.,1997 3 ) and using odds ratios (OR) for mixed treatment comparison (combination of evidence from direct and indirect comparisons to incorporate all available evidence). All analyses were carried out in SAS® v9.1 or above. Results: The systematic review identified 211 studies, of which 34 met inclusion criteria for evaluation. Results of random effects meta-analysis, adjusted indirect comparison and mixed treatment comparison in reducing fracture risk are summarized in Table 1 .
OC20 -EFFICACY OF DENOSUMAB RELATIVE TO OTHER OSTEOPOROSIS THERAPIES FOR PREVENTION OF FRACTURES IN POSTMENOPAUSAL OSTEOPOROSIS: RESULTS OF AN ADJUSTED INDIRECT AND MIXED TREATMENT COMPARISON
Conclusions:
Denosumab therapy was associated with significantly improved reductions in all fracture types evaluated (new vertebral, non-vertebral and hip) compared to placebo. Denosumab was significantly more effective in preventing new vertebral fractures than the current standard of care, oral bisphosphonates. Aims: Women on prescription anti-osteoporosis medications often fail to continue their therapy, with some switching and others discontinuing treatment. We assessed discontinuation of such medications and factors associated with stopping treatment in a large international study. Methods: GLOW is an observational study of non-institutionalized women 55+ recruited by 723 primary physician practices (10 countries). Women visiting practices in prior 2 years were eligible. Self-administered questionnaires were mailed (baseline, 12 months). We collected data on demographics; medical history; risk factors for fracture; fracture occurrence; self-report of prevention, diagnosis & treatment. Women were asked if they had stopped taking any of 10 anti-osteoporosis medications: alendronate, etidronate, ibandronate, pamidronate, risedronate (bisphosphonates), calcitonin, raloxifene, strontium ranelate, teriparatide, tibolone (non-bisphosphonates). Results: 1-year data were available for 32,457 (54%) women. 5321 had been on an anti-osteoporosis medication at baseline; 1029 (19%) reported stopping it around 1 year later. Prevalence of prior fracture, perception of risk, and concomitant use of calcium/vit D did not differ between the 2 populations. Number of concomitant medicines was not a determinant of stopping. Most frequent reasons for stopping were doctor's advice, side effects, & concern about long-term risks (Table) . Side effects or long-term risk was the reason cited by 37%. Similar percentages of women stopped taking non-bisphosphonates as bisphosphonates (20% vs. 18%). More women who stopped bisphosphonates cited difficulty taking the medicine vs. those stopping non-bisphosphonates (7.8% vs. 2.7% p=0.01). When comparing reasons for stopping monthly (N=350) vs. weekly (N=4692) bisphosphonates, more monthly users stopped due to side effects than did weekly users (31% vs. 21%, p=0.046).
The most frequently cited reasons for stopping treatment at 1 year were doctor's advice, side effects and concern over long-term risks. Over twice the percentage of bisphosphonate users who stopped taking medication cited difficulty taking the medicine vs. users of other anti-osteoporosis medications. Aims: Strontium ranelate, has demonstrated its early and sustained antifracture efficacy at the vertebral and nonvertebral levels (1,2). The aim is to evaluate bone quality and to extend up to 60 months the analyses of the distribution and content of strontium (Sr) in bone and its effect on mineralization. Methods: 32 iliac bone biopsies were taken from postmenopausal osteoporotic (PMOP) women after 2, 12, 24, 36, 48 and 60 months of treatment with strontium ranelate (2 g/day; 1,2,3). Samples were investigated both by X-ray microanalysis (4,5) for focal bone Sr uptake and distribution, and by quantitative microradiography (6) for the degree of mineralization of bone (DMB). On 10 of the samples, global Sr distribution was analyzed by Xray cartography on the whole sample surface and the % of surface containing Sr was calculated (4). Results: Sr was heterogeneously distributed into bone tissue and exclusively present in newly formed bone, what corresponded to the bone formation activity during the treatment period. The surfaces of bone containing Sr increased from 2 months (2%) to 36 months of treatment (35%), followed by a smaller increment until 60 months (48%). This evolution was more marked in cancellous (4, 44, 88%, respectively) than in cortical bone (1, 29, 44%, respectively). However, focal bone Sr content remained constant in the new bone from 2 to 60 months of treatment (mean: 0.41±0.12 atomic %). DMB was maintained and its distribution was heterogeneous in cortical, cancellous or total bone, independently of treatment duration. Conclusions: Even after a prolonged treatment with strontium ranelate (up to 60 months), the distribution of Sr corresponded only to formation activity and the quality of bone mineral was preserved, supporting the safety of this treatment at bone tissue level. Aims: The Multiple Outcomes of Raloxifene Evaluation (MORE) study, a placebo controlled phase III trial of raloxifene in postmenopausal osteoporosis, showed that both doses tested (60 mg and 120 mg daily) reduced the risk of vertebral fracture. There was no significant effect on non-vertebral fracture. The aim of the present study was to evaluate the distribution of fracture risk assessed at baseline using the FRAX ® tool in MORE and to determine the efficacy of raloxifene as a function of baseline fracture risk. Methods: The effects of raloxifene (60 and 120 mg daily combined) compared to placebo on the risk of all clinical fractures as well as the risk of morphometric vertebral fracture were examined as a function of baseline fracture risk. Baseline clinical risk factors and BMD were entered in country specific FRAX ® models to compute the 10-year probability of major osteoporotic fractures. No information was available on parental history of hip fracture and this variable was simulated. The interaction between fracture probability and treatment efficacy was examined by Poisson regression. Results: The mean±SD 10-year probability of major osteoporotic fractures (with BMD) was 21±11% (range 0.9-77.2%). Treatment with raloxifene was associated with an 18% decrease in all clinical fractures compared to placebo treatment (hazard ratio HR=0.82; 95% CI=0.71-0.95; p=0.0063) and a 42% decrease in incident morphometric vertebral fractures (HR=0.58; 95% CI=0.48-0.69; p<0.001). Efficacy was shown over the whole range of fracture probability and the interaction between fracture probability and treatment was not significant. The efficacy or raloxifene on vertebral fracture risk was significantly greater at lower ages. At the 90 th percentile of age (75 years) vertebral fracture risk was reduced by 31% irrespective of FRAX ® probabilities. In contrast at younger ages, efficacy was higher and increased further still with decreasing fracture probability. Conclusions: Raloxifene (60 and 120 mg doses combined) significantly decreased the risk of all clinical fractures and morphometric fractures in women. Overall, there was no significant interaction between efficacy and fracture probability. In the case of morphometric vertebral fractures efficacy decreased significantly with increasing age.
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